Semaglutide Side Effects: Common Symptoms, Rare Risks & How to Manage Them

The most frequently reported side effects of semaglutide are gastrointestinal in nature. In the STEP clinical trials, the following side effects occurred more often in semaglutide-treated patients than in the placebo group: nausea (44% vs. 18%), diarrhea (30% vs. 16%), vomiting (24% vs. 6%), constipation (24% vs. 11%), and abdominal pain (20% vs. 11%).

These side effects are most common during the dose escalation phase — the first 16 to 20 weeks of treatment when the dose is gradually increased. Most patients find that nausea peaks during the first week or two after each dose increase and then subsides as the body adjusts. By the time patients reach their maintenance dose, gastrointestinal symptoms have typically resolved or become very manageable.

Other common side effects include headache (14%), fatigue (11%), and injection site reactions such as mild redness or swelling (3-5%). These are generally mild and do not require treatment discontinuation.

Nausea is the most commonly cited reason patients consider stopping semaglutide, but there are several effective strategies for managing it. First, eat smaller, more frequent meals rather than large portions. Since semaglutide slows gastric emptying, large meals can overwhelm the digestive system and worsen nausea.

Avoid high-fat, greasy, or heavily spiced foods, especially during dose escalation periods. These foods are harder to digest and can exacerbate gastrointestinal symptoms. Instead, focus on bland, easy-to-digest foods like crackers, rice, bananas, and lean proteins when nausea is at its worst.

Stay well hydrated by sipping water throughout the day. Dehydration can worsen nausea, and vomiting or diarrhea can lead to fluid loss. Some patients find that ginger tea, peppermint, or over-the-counter anti-nausea medications like ondansetron (prescribed by your clinician) provide additional relief. Eating slowly and stopping at the first sign of fullness is also important — overeating on semaglutide can trigger significant discomfort.

Some patients experience hair thinning (telogen effluvium) during rapid weight loss on semaglutide. This is typically related to the caloric deficit and nutritional changes rather than the medication itself and usually resolves as weight stabilizes. Ensuring adequate protein intake (at least 60-80 grams per day) and taking a daily multivitamin can help minimize this effect.

Gallbladder problems, including gallstones, have been reported in clinical trials at higher rates than placebo (1.6% vs. 0.7% in STEP trials). Rapid weight loss is a known risk factor for gallstone formation regardless of the method used. Symptoms include sudden, intense pain in the upper right abdomen, especially after eating fatty foods. If you experience these symptoms, contact your healthcare provider.

Changes in bowel habits — particularly constipation — are common and can be persistent for some patients. Increasing fiber intake, staying hydrated, and using over-the-counter remedies like polyethylene glycol (MiraLAX) can help. Regular physical activity also promotes healthy bowel function.

Semaglutide carries a boxed warning regarding thyroid C-cell tumors. In animal studies (rodents), GLP-1 receptor agonists caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether semaglutide causes these tumors in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis (inflammation of the pancreas) has been reported in rare cases. Symptoms include severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting. If pancreatitis is suspected, semaglutide should be discontinued immediately. The incidence in clinical trials was low (less than 0.5%), but patients with a history of pancreatitis should discuss risks with their clinician.

Other rare but serious risks include allergic reactions, kidney problems (usually related to dehydration from vomiting or diarrhea), and retinopathy complications in patients with diabetic retinopathy. Patients with a history of suicidal thoughts or behavior should also be monitored, though a causal link with GLP-1 medications has not been established.

While most side effects are manageable at home, certain symptoms warrant prompt medical attention. Contact your healthcare provider if you experience severe or persistent nausea and vomiting that prevents you from keeping food or fluids down for more than 24 hours, as this can lead to dangerous dehydration and electrolyte imbalances.

Seek immediate medical attention for signs of pancreatitis (severe abdominal pain that does not resolve), allergic reactions (swelling of the face, lips, or throat; difficulty breathing; severe rash), or symptoms of thyroid tumors (a lump or swelling in the neck, difficulty swallowing, hoarseness that does not go away).

Also contact your clinician if you experience unusual changes in vision, signs of kidney problems (decreased urination, swelling in the legs or feet), or symptoms of gallbladder disease. It is also important to report any mood changes, including depression or thoughts of self-harm. Your medical team is available to help adjust your treatment plan and manage any concerns that arise during your semaglutide journey.